How to appeal an IVIG Infusion denial
IVIG denials are among the highest-dollar in medicine and hinge on the diagnosis-specific coverage policy, step-therapy, and the drug J-code, payers restrict IVIG to specific approved indications and deny buy-and-bill product outside them.
Common code: CPT 96365-96368 (infusion admin) + J-codes (J1568-J1569, J1459 immune globulin)Why it gets denied
- The diagnosis isn't on the payer's approved IVIG indication list, or the criteria weren't documented
- Step-therapy or prior-treatment requirements weren't met
- Prior authorization lapsed or didn't cover the dose/frequency infused
- The J-code product units or infusion-time units didn't reconcile to the dose
What overturns it
- Map the diagnosis to the payer's covered IVIG indications and document the criteria (e.g. CIDP, MMN findings)
- Document the required prior treatments or contraindications for step-therapy
- Keep prior auth current for the exact product, dose, and frequency and tie it to the claim
- Reconcile the product and infusion-time units to the administration record
Worth appealing? IVIG can run into five figures per infusion in drug cost the practice fronts, so a denial is major capital exposure. These are critical to recover and are winnable when the indication criteria and dosing are documented.
Common questions
How do I appeal an IVIG Infusion denial?
IVIG denials are among the highest-dollar in medicine and hinge on the diagnosis-specific coverage policy, step-therapy, and the drug J-code, payers restrict IVIG to specific approved indications and deny buy-and-bill product outside them. To overturn it: map the diagnosis to the payer's covered IVIG indications and document the criteria (e.g. CIDP, MMN findings); document the required prior treatments or contraindications for step-therapy; keep prior auth current for the exact product, dose, and frequency and tie it to the claim; reconcile the product and infusion-time units to the administration record.
Why do IVIG Infusion claims get denied?
The diagnosis isn't on the payer's approved IVIG indication list, or the criteria weren't documented; Step-therapy or prior-treatment requirements weren't met; Prior authorization lapsed or didn't cover the dose/frequency infused; The J-code product units or infusion-time units didn't reconcile to the dose.
Is a IVIG Infusion denial worth appealing?
IVIG can run into five figures per infusion in drug cost the practice fronts, so a denial is major capital exposure. These are critical to recover and are winnable when the indication criteria and dosing are documented. You pay 25% only on what's recovered, so there's no cost to working the winnable ones.
See how many IVIG Infusion denials you wrote off.
A free assessment shows your real recoverable number. No risk, paid only on what we recover.